Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Status:
Terminated
Trial end date:
2020-08-08
Target enrollment:
Participant gender:
Summary
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with
EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and
Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cullinan Apollo Corporation Cullinan Oncology, LLC